C. A. Tavares

Cross‐protective efficacy from a immunogen firstly identified in Leishmania infantum against tegumentary leishmaniasis

D. Menezes-Souza, B. M. Roatt, D. P. Lage, 2016, Parasite immunology.

Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis

C. Alonso, M. A. Chávez-Fumagalli, M. C. Duarte, 2014, Parasites & Vectors.

Specific Serodiagnosis of Canine Visceral Leishmaniasis Using Leishmania Species Ribosomal Protein Extracts

C. Alonso, V. T. Martins, P. Bonay, 2009, Clinical and Vaccine Immunology.

An optimized nanoparticle delivery system based on chitosan and chondroitin sulfate molecules reduces the toxicity of amphotericin B and is effective in treating tegumentary leishmaniasis

V. Cardoso, M. A. Chávez-Fumagalli, M. C. Duarte, 2014, International journal of nanomedicine.

Identification of Proteins in Promastigote and Amastigote-like Leishmania Using an Immunoproteomic Approach

M. Santoro, M. C. Duarte, E. Coelho, 2012, PLoS neglected tropical diseases.

Novel targeting using nanoparticles: an approach to the development of an effective anti-leishmanial drug-delivery system

D. P. Lage, M. A. Chávez-Fumagalli, M. C. Duarte, 2014, International journal of nanomedicine.

A Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis

D. Menezes-Souza, M. C. Duarte, E. Coelho, 2015, Parasites & Vectors.